Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Voyageur Pharmaceuticals Ltd V.VM

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

Latest News

Voyageur Receives $600K Grant from Alberta Innovates for Product Development


Voyageur Secures $687k of Additional Capital from Warrant Exercises


Voyageur Pharmaceuticals is going global: Why it's time to buy the stock


Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025...


Voyageur Commences Testing of Innovative Barium Contrast Product Line in Human Radiology Scans...


Canadian Investment Regulatory Organization Trade Resumption - VM


Voyageur Pharmaceuticals Ltd. Signs Letter of Intent with Global Contrast Imaging Company to...


Voyageur Announces Closing of Final Tranche of Private Placement


Voyageur Announces Closing of First Tranche of Private Placement


Voyageur Announces Extension to Complete Proposed Private Placement


Voyageur Pharmaceuticals announces $1M raise for contrast drug testing


Voyageur Announces Proposed Private Placement


One of the best Venture pharma stocks has grown even stronger


Voyageur Pharmaceuticals Grants Stock Options


Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim...